New research identifies potential drug target to prevent kidney failure

What is IgAN

The development of a new treatment paradigm for Immunoglobulin A nephropathy (IgAN) is crucial due to its progressive nature and potential to lead to end-stage kidney disease (ESKD). IgAN is the most common form of primary glomerulonephritis, characterized by IgA deposition in the renal mesangium, affecting individuals of various ethnic backgrounds and ages.Current treatment approaches for IgAN primarily focus on supportive therapy, lifestyle modifications, and blood pressure control. However, the efficacy of these treatments, including corticosteroids, remains debated, highlighting the need for novel, well-tolerated disease-modifying therapies. 

Recent advancements in understanding IgAN pathophysiology have led to the introduction of innovative treatment modalities targeting the immunopathogenesis of IgAN. These include complement-targeted therapies and B-cell/plasma cell targeted therapies aimed at improving patient outcomes and slowing disease progression.The evolving landscape of IgAN treatment underscores the importance of developing a comprehensive treatment paradigm that addresses the underlying pathophysiology of the disease while improving patient quality of life and long-term outcomes. 

This shift towards precision medicine and personalized therapy holds promise in reducing morbidity and mortality rates associated with IgAN, emphasizing the need for tailored approaches to meet the specific needs of patients with this condition.

Challenges facing to treat

Treating kidney disease presents various challenges, especially in settings where access to healthcare is limited. A case report highlighted the difficulties faced in managing kidney failure in a free clinic setting, emphasizing the impact of socioeconomic factors, comorbidities, and delayed access to care on disease progression. 

The report described a patient with stage 3 kidney disease who faced gaps in care due to being medically uninsured, underscoring the barriers faced by vulnerable populations in receiving timely and appropriate treatments for kidney conditions.Moreover, the complexity of chronic kidney disease (CKD) management lies in its progressive nature and the need for interventions that not only address symptoms but also slow down disease advancement. 

CKD is often silent until its later stages, leading to missed opportunities for early intervention and prevention of adverse outcomes. Additionally, the financial burden associated with CKD treatment, including dialysis and medications, poses a significant challenge for patients, as highlighted by Medicare spending statistics related to CKD and kidney failure treatment.Overall, challenges in treating kidney disease encompass issues related to healthcare access, delayed diagnosis, socioeconomic disparities, and the financial strain of long-term management. Addressing these challenges requires a comprehensive approach focusing on early detection, patient education, improved access to care, and ongoing support for individuals with kidney conditions.

Why it is diffucut to treat?

IgA nephropathy is challenging to treat due to several factors. Despite optimized supportive care, some patients fail to achieve disease control and experience progressive deterioration of kidney function. 

The disease's complexity lies in its progressive nature, where individuals with greater degrees of proteinuria, hypertension, or reduced kidney function have a moderately poor long-term prognosis. Additionally, the treatment of IgA nephropathy is complicated by the immune complex-driven kidney inflammation and damage, necessitating novel therapies to reduce these effects.Moreover, IgA nephropathy poses challenges due to its potential to lead to end-stage renal disease (ESRD), making it the leading cause of kidney failure. The disease can cause complications such as high blood pressure, high cholesterol, acute kidney failure, nephrotic syndrome, and a range of symptoms associated with ESRD, including changes in urination, nausea, fatigue, anemia, and more. 

Furthermore, kidney transplants, while a treatment option for ESRD, can be challenging due to the risk of IgA nephropathy recurrence in transplanted kidneys and the limited availability of donor kidneys.

Risk factors

The risk factors for developing IgA nephropathy include various elements such as family history of chronic nephritis, susceptibility to the common cold, preference for salty foods, frequent consumption of raw eggs, high intake of carbohydrates (including rice), alcohol consumption, use of antioxidant vitamin supplements, high intake of protein, fat, monounsaturated fatty acids, and all/n-3 polyunsaturated fatty acids. 

Additionally, factors like male gender, hypertension, renal insufficiency, hyperuricaemia, hypertriglyceridaemia, diabetes, smoking, and high body mass index have been associated with an increased risk of vascular diseases in IgA nephropathy patients. 

These risk factors play a significant role in the development and progression of IgA nephropathy, highlighting the importance of understanding and managing these factors to improve patient outcomes.

What is the prevalence of IgA nephropathy?

The prevalence of IgA nephropathy (IgAN) varies significantly across different populations. It is reported to be more frequent in Asian populations, with 45 cases per million population per year in Japan, compared to 31 cases per million population per year in Caucasians in France. 

This disparity in prevalence is influenced by various factors such as systematic mass screening of urine in some Asian countries like Hong Kong, Japan, Korea, and Singapore, which is not common in Western countries. 

Additionally, differences in the recognition of persistent microscopic hematuria by healthcare professionals and varying practices regarding kidney biopsies contribute to the observed variations in IgAN prevalence among different populations.

What is the global incidence of IgA nephropathy?

The global incidence of IgA nephropathy (IgAN) varies across different regions and populations. Studies have reported that the worldwide incidence of IgAN ranges from 0.06 per 100,000 in South Africa to 4.2 per 100,000 in Japan. 

Additionally, a systematic review of biopsy-based studies spanning multiple countries suggested an overall population incidence of at least 2.5 per 100,000. These findings highlight the variability in IgAN incidence globally, with higher rates observed in certain regions such as Asia compared to others.

How does it affects our lifestyle?

IgA nephropathy (IgAN) can significantly impact lifestyle due to its chronic nature and potential complications. Patients with IgAN may face challenges related to managing their kidney health, including the need for regular monitoring of kidney function, blood pressure control, and dietary modifications to reduce proteinuria and slow disease progression. 

Lifestyle changes such as increased physical exercise, alcohol cessation, and adherence to prescribed medications are often recommended to improve renal outcomes in IgAN patients. Additionally, the emotional and psychological burden of living with a chronic kidney condition like IgAN can affect daily life, leading to concerns about disease progression, treatment adherence, and overall quality of life. 

Overall, IgA nephropathy can impact various aspects of an individual's lifestyle, necessitating a multidisciplinary approach to manage the disease effectively and improve patient outcomes.

The Bottom Line

The conclusion drawn from the study on IgA nephropathy (IgAN) risk factors indicates that patients with specific pathological assessments, including M1, low baseline eGFR, TA-Hb, and high TA-UA, are more likely to progress to end-stage renal disease (ESRD). 

The research compared the Oxford score of primary IgAN patients in China and identified M1 as a significant risk factor for ESRD progression. Additionally, the study highlighted the importance of factors like serum UA, Hb levels, and TA-P in influencing renal outcomes in IgAN patients. While the study had limitations such as its retrospective nature and selection bias, it emphasized the need for long-term prospective studies or clinical trials to further investigate IgAN treatment strategies. 

Overall, the findings underscore the significance of specific pathological markers and clinical factors in predicting the progression of IgAN to ESRD, providing valuable insights for managing this complex kidney condition.